Fractal analysis of CT perfusion images for evaluation of antiangiogenic treatment and survival in hepatocellular carcinoma

Academic Radiology

Volumn 21, Issue 5, 2014, Pages 654-660

  Hayano, Koichi ^a   Lee, Sang Ho ^a   Yoshida, Hiroyuki ^a   Zhu, Andrew X ^a   Sahani, Dushyant V ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Angiogenesis; Antiangiogenic treatment; CT perfusion; Hepatocellular carcinoma; Heterogeneity

Indexed keywords

BEVACIZUMAB; GEMCITABINE; IOPAMIDOL; OXALIPLATIN; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ADIABATICITY; ADULT; ADVANCED CANCER; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CELL HETEROGENEITY; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPUTED TOMOGRAPHY PERFUSION; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED SCINTIGRAPHY; CONTINUOUS INFUSION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; FRACTAL ANALYSIS; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; IMAGING SOFTWARE; LIVER CELL CARCINOMA; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGICAL PARAMETERS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PORTAL VEIN BLOOD FLOW; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; TISSUE PERFUSION; TUMOR VASCULARIZATION; AUTOMATED PATTERN RECOGNITION; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; COMPUTER ASSISTED DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; NEOVASCULARIZATION, PATHOLOGIC; PHASE 2 CLINICAL TRIAL; PROCEDURES; PROGNOSIS; RADIOGRAPHY; REPRODUCIBILITY; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; SURVIVAL; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, HEPATOCELLULAR; FEMALE; FRACTALS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PATTERN RECOGNITION, AUTOMATED; PERFUSION IMAGING; PROGNOSIS; RADIOGRAPHIC IMAGE INTERPRETATION, COMPUTER-ASSISTED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84897497709     PISSN: 10766332     EISSN: 18784046     Source Type: Journal    
DOI: 10.1016/j.acra.2014.01.020     Document Type: Article

References (41)

1. Ferlay J., Shin H.R., Bray F., et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
2. Miura H., Miyazaki T., Kuroda M., et al. Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J Hepatol 1997, 27:854-861.
3. Yamaguchi R., Yano H., Iemura A., et al. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 1998, 28:68-77.
4. Zhu A.X., Duda D.G., Sahani D.V., et al. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol 2011, 8:292-301.
5. Poon R.T., Ho J.W., Tong C.S., et al. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 2004, 91:1354-1360.
6. Chao Y., Li C.P., Chau G.Y., et al. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol 2003, 10:355-362.
7. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
8. Muntane J., De la Rosa A.J., Docobo F., et al. Targeting tyrosine kinase receptors in hepatocellular carcinoma. Curr Cancer Drug Targets 2013, 13:300-312.
9. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
10. Desar I.M., van Herpen C.M., van Laarhoven H.W., et al. Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev 2009, 35:309-321.
11. Zhu A.X., Holalkere N.S., Muzikansky A., et al. Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma. Oncologist 2008, 13:120-125.
12. Zhu A.X., Sahani D.V., Duda D.G., et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009, 27:3027-3035.
13. Sahani D.V., Jiang T., Hayano K., et al. Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy. J Hematol Oncol 2013, 6:51. 8722-6-51.
14. Jain R.K., Duda D.G., Willett C.G., et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009, 6:327-338.
15. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001, 7:987-989.
16. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
17. Goel S., Duda D.G., Xu L., et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011, 91:1071-1121.
18. Mandelbrot B.B. The fractal geometry of nature 1982, W.H.Freeman and Company, New York.
19. Kido S., Kuriyama K., Higashiyama M., et al. Fractal analysis of small peripheral pulmonary nodules in thin-section CT: evaluation of the lung-nodule interfaces. J Comput Assist Tomogr 2002, 26:573-578.
20. Huang Y.L., Chen J.H., Shen W.C. Diagnosis of hepatic tumors with texture analysis in nonenhanced computed tomography images. Acad Radiol 2006, 13:713-720.
21. Hung S.H., Lin C.Y., Lee J.Y., et al. Computed tomography image characteristics of metastatic lymph nodes in patients with squamous cell carcinoma of the head and neck. Auris Nasus Larynx 2012, 39:606-610.
22. Cui C., Cai H., Liu L., et al. Quantitative analysis and prediction of regional lymph node status in rectal cancer based on computed tomography imaging. Eur Radiol 2011, 21:2318-2325.
23. Jiang T., Kambadakone A., Kulkarni N.M., et al. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). Invest Radiol 2012, 47:11-17.
24. Zhu A.X., Blaszkowsky L.S., Ryan D.P., et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006, 24:1898-1903.
25. Zhu F., Carpenter T., Rodriguez Gonzalez D., et al. Computed tomography perfusion imaging denoising using gaussian process regression. Phys Med Biol 2012, 57:N183-N198.
26. Ibanez L., Schroeder W., Ng L., et al. The ITK software guide 2003, Kitware Inc., Clifton Park, NY.
27. St Lawrence K.S., Lee T.Y. An adiabatic approximation to the tissue homogeneity model for water exchange in the brain: I. Theoretical derivation. J Cereb Blood Flow Metab 1998, 18:1365-1377.
28. Sahani D.V., Holalkere N.S., Mueller P.R., et al. Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue-initial experience. Radiology 2007, 243:736-743.
29. Goh V., Liaw J., Bartram C.I., et al. Effect of temporal interval between scan acquisitions on quantitative vascular parameters in colorectal cancer: implications for helical volumetric perfusion CT techniques. AJR Am J Roentgenol 2008, 191:W288-W292.
30. Leung D.W., Cachianes G., Kuang W.J., et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-1309.
31. Gillies R.J., Schornack P.A., Secomb T.W., et al. Causes and effects of heterogeneous perfusion in tumors. Neoplasia 1999, 1:197-207.
32. Gullino P.M. Tumor pathophysiology: the perfusion model. Antibiot Chemother 1980, 28:35-42.
33. Vaupel P., Kallinowski F., Okunieff P. Blood flow, oxygen consumption and tissue oxygenation of human tumors. Adv Exp Med Biol 1990, 277:895-905.
34. Willett C.G., Boucher Y., di Tomaso E., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004, 10:145-147.
35. Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473:298-307.
36. Matsumoto S., Batra S., Saito K., et al. Antiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia. Cancer Res 2011, 71:6350-6359.
37. Hayano K., Shuto K., Koda K., et al. Quantitative measurement of blood flow using perfusion CT for assessing clinicopathologic features and prognosis in patients with rectal cancer. Dis Colon Rectum 2009, 52:1624-1629.
38. Goh V., Sanghera B., Wellsted D.M., et al. Assessment of the spatial pattern of colorectal tumour perfusion estimated at perfusion CT using two-dimensional fractal analysis. Eur Radiol 2009, 19:1358-1365.
39. Rose C.J., Mills S., O'Connor J.P., et al. Quantifying heterogeneity in dynamic contrast-enhanced MRI parameter maps. Med Image Comput Comput Assist Interv 2007, 10:376-384.
40. Agrawal G., Su M.Y., Nalcioglu O., et al. Significance of breast lesion descriptors in the ACR BI-RADS MRI lexicon. Cancer 2009, 115:1363-1380.
41. Rose C.J., Mills S.J., O'Connor J.P., et al. Quantifying spatial heterogeneity in dynamic contrast-enhanced MRI parameter maps. Magn Reson Med 2009, 62:488-499.